#India #Bengaluru #Biocon #HER2-positive #Pertuzumab

Biocon's Pertuzumab Secures EMA Approval Recommendation

Biocon Biologics Limited, the wholly-owned subsidiary of Biocon Limited, has recently achieved a groundbreaking milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for its biosimilar Pertuzumab. This recommendation is particularly significant as it is the first monoclonal antibody biosimilar approved under the new tailored clinical approach by the EMA. The product, branded as Pebrilzo®, is aimed at treating HER2-positive breast cancer, addressing a major healthcare need across Europe.

Understanding Pertuzumab and Its Implications

Pertuzumab is a monoclonal antibody that plays a crucial role in battling cancers characterized by the overexpression of the HER2 protein. The approval for Pebrilzo® comes following a comprehensive review of the marketing authorization application submitted by Biocon Biologics Ireland Limited. The company is dedicated to expanding access to effective biological therapies and believes this biosimilar will enhance treatment options for patients battling HER2-positive breast cancer, especially in various stages of the disease.

As Shreehas Tambe, the CEO and Managing Director of Biocon, stated, this positive opinion marks an essential stride towards improving access to biologic therapies within Europe. The use of advanced analytical approaches combined with solid clinical pharmacology evidence provides the regulatory assurance necessary to establish biosimilarity between Pebrilzo® and the original biologic.

Pertuzumab's Rich Therapeutic Application

Pebrilzo® is indicated for use alongside Trastuzumab and chemotherapy treatments for adult patients suffering from locally advanced, inflammatory, or early-stage HER2-positive breast cancer classified as high risk for recurrence. It is also recommended for adults diagnosed with HER2-positive metastatic breast cancer, provided they have yet to receive prior anti-HER2 therapies or chemotherapy specific to their metastatic situation. The evidence supporting the efficacy and safety of Pebrilzo®, showcased through rigorous clinical testing, reinforces its resemblance to the reference biologic, ensuring no meaningful differences pertain to quality, safety, or efficacy.

Next Steps and Regulatory Horizon

The European Commission is now poised to conduct a final review of the application with a decision anticipated soon. If the decision remains positive, the Summary of Product Characteristics (SmPC) will be available in all the official languages of the European Union, while comprehensive details will be disseminated on the EMA’s website following the final ruling. Until this authorization is granted, Pebrilzo® remains unauthorized for use in the European Union, underlining the critical importance of regulatory pathways in the healthcare sector.

About Biocon Limited

Established in Bengaluru, India, Biocon Limited has made significant contributions to the biopharmaceutical landscape. The company aims to provide patients worldwide with affordable and life-altering medicines. Biocon engages in addressing a wide array of healthcare challenges, focusing on both chronic and non-communicable diseases through its extensive portfolio of biosimilars and generics. To date, Biocon has launched 12 biosimilar products and over 30 generic formulations globally, making meaningful impacts in areas of high unmet healthcare needs like oncology, immunology, and more.

Biocon holds a commendable position within the global biosimilars landscape, evidenced by its continued commitment to innovation and rigorous R&D efforts. With future potential offerings on the horizon — driven by a robust pipeline and integrated model for lab-to-market supply — Biocon stands resolutely focused on enhancing healthcare outcomes for patients everywhere.

For further information, visit Biocon's official website or follow them on X and LinkedIn.